This article is more than 5 years old. Information may no longer be current.

Bioventus extends distribution agreement of HA treatment for OA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bioventus announced in a press release that it has entered into an agreement with the Seikagaku Corporation to extend distribution of Supartz FX in the United States.

According to the release, the original distribution agreement for the hyaluronic acid (HA) injection used to treat knee osteoarthritis expires on May 2017. Under the extension, Bioventus will continue to distribute Supartz FX in the United States through May 2019.

“We are pleased that Bioventus will continue to provide physicians and patients with Supartz FX beyond 2017,” Tony Bihl, chief executive officer of Bioventus, said in the release.  “HA products like Supartz FX underscore our mission to help people resume and enjoy active lives.”

References:

www.bioventusglobal.com

www.supartzfx.com/what-is-supartz/